SHENZHEN, China and BOSTON-XtalPi, a physics-based, AI-powered pharmatech, announced a partnership with MIT Professor of Chemistry Bradley L. Pentelute to advance research in peptide chemistry and molecular biology.
Professor Pentelute is a Professor of Chemistry, Massachusetts Institute of Technology, and an associate member of the Broad Institute of MIT and Harvard. He is the winner of the Makineni Lectureship from the American Peptide Society, the Eli Lilly Award in Biological Chemistry and Bristol-Myers Squibb Innovation Award.
Professor Pentelute holds a Ph.D. in organic chemistry from the University of Chicago where he was part of the Kent lab. He completed his postdoctoral research at John Collier’s lab at Harvard Medical School. He is the author of over 100 publications.
Professor Pentelute’s research develops new protein modification chemistries, adapts nature's machines for efficient macromolecule delivery into cells, invents flow-based technologies for rapid biopolymer production, and discovers peptide binders to therapeutic protein targets.
The partnership aims to combine Professor Pentelute’s expertise in peptide chemistry and molecular biology with XtalPi’s expertise in artificial intelligence and robotic automation.
“We’re excited to partner with Brad,” said Dr. Shuhao Wen, co-founder and Chairman of XtalPi. “I have known Brad for many years, not only is he an impactful professor at MIT, but also a leading individual in the Boston scientific community. Brad’s deep research experience will be invaluable to XtalPi as we grow and advance our drug discovery platform to serve patients worldwide.”
“I look forward to partnering with XtalPi and invent new chemistry for the efficient and selective modification of proteins and enhance their therapeutic properties to change patients’ lives in China and around the world.” commented Professor Pentelute.
We are a quantum physics-based, AI-powered pharmatech platform dedicated to improving the speed, scale, novelty and success rate of drug discovery and development. With operations in both China and the U.S., we deploy the latest research and computational breakthroughs from around the world for our partners and collaborators.
Our technology platform combines cloud supercomputing-powered in silico tools with a high-throughput wet lab. Our integrated dry lab and wet lab capabilities form an iterative feedback loop that empowers continuous innovation and makes us one of the global leading pharmatech platforms.
SHENZHEN, China & BOSTON - Signet Therapeutics and XtalPi Inc., a physics-based, AI-powered drug R&D company, announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet. The two companies entered into a strategic collaboration in 2020 and successfully identified pre-clinical candidates for a new gastric cancer target in approximately six months. The follow-on project will continue to combine XtalPi’s AI drug discovery platform with Signet’s unique novel organoid disease models to generate pipeline candidates and advance them toward clinical trials.
CAMBRIDGE, Mass., March 23, 2021 -- XtalPi, an artificial intelligence (AI) drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to Drugging the Undruggable disease targets. The investment round totaled $46 million and was led by BGF, with participation from XtalPi and a panel of new and existing investors. XtalPi Chief Strategy Officer (CSO) Dr. Alan Jiang will join PhoreMost Board of Directors.
XtalPi and PhoreMost sign drug discovery collaboration to discover novel inhibitors of "undruggable" targets